Using tumor volumes measured at day 16, we generated a dose response curve to determine the IC50 concentration for VCR (0.25mg/kg) that later would be used for the combination therapy with RCM1 (Supplementary Figure S2C). Here, TNNI3 is linked to neoplasm.